LIF Activators
LIF activators encompass a group of chemical entities that are capable of promoting the activity of Leukemia Inhibitory Factor (LIF), a pleiotropic cytokine belonging to the interleukin-6 family. LIF exerts its biological effects by binding to a specific cell surface receptor complex, which is composed of two subunits: the low-affinity LIF receptor (LIFR) and the signal-transducing subunit gp130. Upon LIF binding, this receptor complex dimerizes, triggering a cascade of intracellular signaling pathways, including JAK/STAT, MAPK, and PI3K/Akt pathways. These pathways are involved in the regulation of cell proliferation, differentiation, and survival across a variety of cell types. LIF activators, therefore, enhance the natural biological functions of LIF by increasing its stability, promoting its interaction with LIFR, or potentiating the downstream signaling events following receptor activation. This can be achieved through various molecular mechanisms, such as stabilizing the cytokine itself, facilitating the cytokine-receptor interaction, or enhancing the receptor's responsiveness to LIF.
The chemical structures of LIF activators are diverse, with the potential to include small molecules, peptides, or other biologic agents that can interact with the LIF signaling pathway. Small molecules might be designed to bind to allosteric sites on the LIF receptor, inducing conformational changes that lead to increased affinity for LIF or heightened receptor activation. Peptides or peptide mimetics could be crafted to mimic the structure of LIF itself, competitively binding to LIFR with greater efficacy than the natural ligand. Alternatively, biologic agents such as antibodies or scaffold proteins could be engineered to bring the receptor subunits into closer proximity, facilitating receptor dimerization and activation in the presence of LIF.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
2-Amino-6-chloro-α-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic Acid Ethyl Ester | 305834-79-1 | sc-479756 | 25 mg | $380.00 | ||
SC79 activates Akt by inhibiting its dephosphorylation, impacting the PI3K/Akt pathway. By enhancing Akt signaling, this compound may potentially modulate LIF activation, as the PI3K/Akt pathway is implicated in cellular processes, including cell survival and proliferation. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
A83-01 is a TGF-β type I receptor inhibitor, influencing the TGF-β signaling pathway. By inhibiting TGF-β receptor activity, this compound can potentially impact LIF activation, as TGF-β signaling is intricately involved in the regulation of cell growth and differentiation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor affecting the MAPK/ERK pathway. By inhibiting MEK, this compound can potentially impact LIF activation, as the MAPK/ERK pathway is intricately involved in the regulation of cell proliferation, differentiation, and survival. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a phosphoinositide 3-kinase (PI3K) inhibitor, influencing the PI3K/Akt pathway. By inhibiting PI3K, this compound can potentially modulate LIF activation, as the PI3K/Akt pathway plays a role in cell growth, differentiation, and immune response regulation. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is a TGF-β type I receptor inhibitor, influencing the TGF-β signaling pathway. By inhibiting TGF-β receptor activity, this compound can potentially impact LIF activation, as TGF-β signaling is intricately involved in the regulation of cell growth and differentiation. | ||||||
Stat3 Inhibitor VI, S3I-201 | 501919-59-1 | sc-204304 | 10 mg | $151.00 | 104 | |
S3I-201 inhibits STAT3 dimerization, affecting the JAK/STAT pathway. By disrupting STAT3 signaling, this compound may potentially modulate LIF activation, as the JAK/STAT pathway is crucial for cellular responses, inflammation, and immune regulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, affecting the PI3K/Akt pathway. By inhibiting PI3K, this compound can potentially modulate LIF activation, as the PI3K/Akt pathway plays a role in cell growth, differentiation, and immune response regulation. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
SB202190 is a p38 MAPK inhibitor affecting the MAPK signaling pathway. By inhibiting p38 MAPK, this compound can potentially modulate LIF activation, as the MAPK pathway is implicated in cellular processes, including inflammation, immune regulation, and cell survival. | ||||||